Δ20 IFITM2 differentially restricts X4 and R5 HIV-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 27, 2017, Pages 7112-7117

  Wu, Wan Lin ^a   Grotefend, Christopher Robert ^a   Tsai, Ming Ting ^a   Wang, Yi Ling ^a   Radic, Vladimir ^a   Eoh, Hyungjin ^a   Huang, I Chueh ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gatekeeping; HIV; Interferon inducible transmembrane protein; Viral entry; 20 IFITM2

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DELTA20 INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 2; INTERFERON INDUCIBLE TRANSMEMRANE PROTEIN 3; MEMBRANE PROTEIN; RETINA S ANTIGEN; UNCLASSIFIED DRUG; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; CXCR4 PROTEIN, HUMAN; EPITOPE; IFITM2 PROTEIN, HUMAN; ISOPROTEIN;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CLINICAL OUTCOME; CONTROLLED STUDY; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; VIRION; VIRUS ENTRY; VIRUS REPLICATION; ALLELE; CLASSIFICATION; GENE FREQUENCY; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; VIROLOGY;

ADAPTIVE IMMUNITY; ALLELES; CELL MEMBRANE; EPITOPES; GENE FREQUENCY; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; JURKAT CELLS; MEMBRANE PROTEINS; PROTEIN ISOFORMS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; VIRION;

EID: 85021764263     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1619640114     Document Type: Article

References (44)

1. Brass AL, et al. (2009) The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139:1243-1254.
2. Huang IC, et al. (2011) Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7:e1001258.
3. Diamond MS, Farzan M (2013) The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 13:46-57.
4. Bailey CC, Huang IC, Kam C, Farzan M (2012) Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8:e1002909.
5. Everitt AR, et al.; GenISIS Investigators; MOSAIC Investigators (2012) IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519-523.
6. Mills TC, et al. (2014) IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis 209:1028-1031.
7. Wang Z, et al. (2014) Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 111:769-774.
8. Foster TL, et al. (2016) Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 20:429-442.
9. Amini-Bavil-Olyaee S, et al. (2013) The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452-464.
10. Williams DE, et al. (2014) IFITM3 polymorphism rs12252-C restricts influenza A viruses. PLoS One 9:e110096.
11. Feeley EM, et al. (2011) IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 7:e1002337.
12. Lu J, et al. (2011) The IFITM proteins inhibit HIV-1 infection. J Virol 85:2126-2137.
13. Compton AA, et al. (2014) IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16:736-747.
14. Compton AA, et al. (2016) Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep 17:1657-1671.
15. Yu J, et al. (2015) IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep 13:145-156.
16. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433-444.
17. Herold N, et al. (2014) HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. J Virol 88: 13956-13970.
18. de la Vega M, et al. (2011) Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology 8:99.
19. McClure MO, Marsh M, Weiss RA (1988) Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J 7:513-518.
20. Stein BS, et al. (1987) pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49:659-668.
21. GTEx (2016) The GTEx Project. Gene expression for IFITM2. Available at https://gtexportal. org/home/gene/IFITM2. Accessed April 2, 2017.
22. Jia R, et al. (2012) The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 86:13697-13707.
23. Wilen CB, Tilton JC, Doms RW (2012) HIV: Cell binding and entry. Cold Spring Harb Perspect Med 2:a006866.
24. Maddon PJ, et al. (1988) HIV infection does not require endocytosis of its receptor, CD4. Cell 54:865-874.
25. Yu D, Wang W, Yoder A, Spear M, Wu Y (2009) The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog 5:e1000633.
26. Bedinger P, et al. (1988) Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 334:162-165.
27. OppermannM(2004) Chemokine receptor CCR5: Insights into structure, function, and regulation. Cell Signal 16:1201-1210.
28. Delwart EL, et al. (1998) Human immunodeficiency virus type 1 populations in blood and semen. J Virol 72:617-623.
29. Bergey EJ, et al. (1994) Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr 7:995-1002.
30. Patterson BK, et al. (1998) Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 153:481-490.
31. Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1: The 'gatekeeper' problem resolved?. Nat Rev Microbiol 4:312-317.
32. Grivel JC, Shattock RJ, Margolis LB (2011) Selective transmission of R5 HIV-1 variants: Where is the gatekeeper?. J Transl Med 9(Suppl 1):S6.
33. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG (2003) Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51:229-240.
34. Tscherning C, et al. (1998) Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241:181-188.
35. Wu Y, Yoder A (2009) Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 5:e1000520.
36. Amara A, et al. (2003) G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol 77:2550-2558.
37. Melikyan GB (2014) HIV entry: A game of hide-and-fuse?. Curr Opin Virol 4:1-7.
38. Wakim LM, Gupta N, Mintern JD, Villadangos JA (2013) Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol 14:238-245.
39. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752.
40. Huang IC, et al. (2008) Influenza A virus neuraminidase limits viral superinfection. J Virol 82:4834-4843.
41. Campeau E, et al. (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4:e6529.
42. Nolan T, Hands RE, Bustin SA (2006) Quantification of mRNA using real-time RT-PCR. Nat Protoc 1:1559-1582.
43. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
44. Tada T, et al. (2015) MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med 21:1502-1507.